PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
G&A reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
264.51%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
3.15%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
3.15%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
-0.34%
Both companies reducing interest expense. Martin Whitman would check industry trends.
-75.00%
D&A reduction while TRVN shows 6.74% growth. Joel Greenblatt would examine efficiency.
15.50%
EBITDA growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
16.24%
Operating income growth 1.25-1.5x TRVN's 14.24%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
-3.90%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.90%
Tax expense growth while TRVN reduces burden. John Neff would investigate differences.
12.65%
Net income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
12.55%
EPS growth while TRVN declines. John Neff would investigate advantages.
12.55%
Diluted EPS growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.